ARGX vs. CVS: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ARGX and CVS, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
CVS towers over ARGX with a market cap of 78.57 billion USD, roughly 2.20 times the 35.72 billion USD of its peer.
CVS dances to a riskier tune, sporting a beta of 0.60, while ARGX keeps it calmer at 0.17.
Worth noting: ARGX flies the ADR flag, tying it to a foreign outfit on U.S. soil, while CVS sticks to plain-vanilla U.S. listing.
| Symbol | ARGX | CVS |
|---|---|---|
| Company Name | argenx SE | CVS Health Corporation |
| Country | NL | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Healthcare Plans |
| CEO | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | Mr. J. David Joyner CEBS |
| Price | 584.95 USD | 62.11 USD |
| Market Cap | 35.72 billion USD | 78.57 billion USD |
| Beta | 0.17 | 0.6 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 18, 2017 | November 20, 1996 |
| ADR | Yes | No |
Performance Comparison
This chart compares the performance of ARGX and CVS over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ARGX and CVS based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ARGX shows a negative Price-to-Free Cash Flow of -457.12, meaning it’s been burning through cash faster than it can produce it over the past twelve months—a troubling sign for its financial resilience. On the flip side, CVS at 13.23 has managed to keep its cash flow in positive territory.
| Symbol | ARGX | CVS |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 51.21 | 14.83 |
| Forward PEG Ratio (TTM) | 1.36 | 1.27 |
| Price-to-Sales Ratio (P/S, TTM) | 16.54 | 0.21 |
| Price-to-Book Ratio (P/B, TTM) | 7.77 | 1.02 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -457.12 | 13.23 |
| EV-to-EBITDA (TTM) | 4584.81 | 10.98 |
| EV-to-Sales (TTM) | 15.88 | 0.40 |
| EV-to-Free Cash Flow (TTM) | -438.95 | 25.20 |
Dividend Comparison
ARGX pays no dividends, focusing all profits on growth, appealing to capital-gains investors. Meanwhile, CVS’s 4.28% yield rewards shareholders, showing financial confidence while supporting objectives—a contrast to ARGX’s growth-only approach.
| Symbol | ARGX | CVS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.28% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ARGX and CVS, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- CVS’s current ratio of 0.82 dips below 1, leaving short-term liabilities larger than current assets—a scenario that could hinge on cash flow support. On the other hand, ARGX at 7.29 has enough assets to handle its obligations.
- At 0.63, CVS’s quick ratio falls below 0.8, where liquid assets, minus inventory, can’t keep up with short-term bills—possibly riding on cash flow. By contrast, ARGX hits 6.68, covering its bases comfortably.
- ARGX clocks in at -20.85 below 1.5, earnings just keeping ahead of interest—dicey if profits stumble. By contrast, CVS’s 3.18 sails through with plenty of cushion.
| Symbol | ARGX | CVS |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 0.82 |
| Quick Ratio (TTM) | 6.68 | 0.63 |
| Debt-to-Equity Ratio (TTM) | 0.01 | 1.06 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.32 |
| Interest Coverage Ratio (TTM) | -20.85 | 3.18 |